GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (LTS:0M26) » Definitions » Research & Development

XOMA Royalty (LTS:0M26) Research & Development : $2.88 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is XOMA Royalty Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. XOMA Royalty's Research & Development for the three months ended in Dec. 2024 was $0.86 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was $2.88 Mil.

XOMA Royalty Research & Development Historical Data

The historical data trend for XOMA Royalty's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty Research & Development Chart

XOMA Royalty Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.17 0.15 0.14 2.88

XOMA Royalty Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 1.16 0.82 0.86

XOMA Royalty Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XOMA Royalty  (LTS:0M26) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

XOMA Royalty Research & Development Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

XOMA Royalty Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (LTS:0M26) » Definitions » Research & Development
Comparable Companies
NVCT CDTX ITOS ABEO MNPR ANNX DSGN AVIR OCGN CDXS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
XOMAO.PFD:USA XOMAP.PFD:USA XOMA:USA X0M1:Germany
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
Website
https://www.xoma.com
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

XOMA Royalty Headlines

No Headlines